Top

Cancer Immunology, Immunotherapy

Published in:

Open Access 01-06-2024 | Ovarian Cancer | Correction

Correction to: Dominant‑negative transforming growth factor‑β receptor‑armoured mesothelin‑targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer

Authors: Ke Li, Jing Xu, Jing Wang, Chong Lu, Yilin Dai, Qing Dai, Wang Zhang, Congjian Xu, Shu Wu, Yu Kang

Published in: Cancer Immunology, Immunotherapy | Issue 6/2024

Excerpt

Correction to: Cancer Immunology, Immunotherapy (2023) 72:917–928 https://doi.org/10.1007/s00262-022-03290-6 …

Title: Correction to: Dominant‑negative transforming growth factor‑β receptor‑armoured mesothelin‑targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer
Authors: Ke Li
Jing Xu
Jing Wang
Chong Lu
Yilin Dai
Qing Dai
Wang Zhang
Congjian Xu
Shu Wu
Yu Kang
Publication date: 01-06-2024
Publisher: Springer Berlin Heidelberg
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: Cancer Immunology, Immunotherapy / Issue 6/2024
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-024-03668-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2024

New genetic insights into immunotherapy outcomes in gastric cancer via single-cell RNA sequencing and random forest model

Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy

T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC

A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma

CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival

Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms

Keynote webinar | Spotlight on antibody–drug conjugates in cancer